Nearly 44 percent of adults ranked staying up to date on vaccines as important before the COVID-19 pandemic, rising to 65 percent after the pandemic, according to a new survey by Kantar on behalf of...
Gilead recently announced that a three-day course of its COVID-19 treatment, remdesivir, elicited an 87 percent reduction in risk for the composite primary endpoint of COVID-19-related hospitalization...
FDA recently amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine to allow for a single booster dose six months after completing the primary series.
In December 2020,...
Johnson & Johnson recently announced that a booster shot of its COVID-19 vaccine elicited 94 percent protection against coronavirus in a Phase 3 clinical trial.
The largest real-world...
Pfizer and BioNTech recently announced that two doses of their COVID-19 vaccine elicited neutralizing antibody responses in pediatric patients in a Phase 2/3 clinical trial.
In the trial,...
National Resilience recently entered into a multi-year agreement with Moderna to manufacture drug substance mRNA for its COVID-19 vaccine.
Resilience is a manufacturing and technology company...
Roche recently signed a definitive share purchase agreement to acquire 100 percent of the outstanding shares of TIB Molbiol Group to enhance its molecular diagnostic solutions portfolio.
The...
Moderna recently submitted initial data to the FDA to evaluate a booster dose of its COVID-19 vaccine, mRNA-1263, at the 50 microgram dose level.
The company will submit data to the European...
The AMA, American Pharmacists Association (APhA), and American Society of Health-System Pharmacists (ASHP) have called for an “immediate end” to the prescribing, dispensing, and use of...
Pfizer and BioNTech recently signed a letter of intent with Eurofarma Laboratoriors SA, a Brazilian pharmaceutical company, to manufacture its COVID-19 vaccine, Comirnaty, in Latin...
COVID-19 convalescent plasma given to high-risk outpatients within one week of the onset of coronavirus symptoms does not prevent disease progression, according to a New England Journal of Medicine...
Johnson & Johnson recently announced that a booster dose of its COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after...
AstraZeneca recently announced that its COVID-19 antibody combination, AZD442, reduced the risk of symptomatic coronavirus by 77 percent compared to placebo in a Phase 3 trial.
The randomized,...
FDA has granted full approval to Pfizer and BioNTech’s COVID-19 vaccine for individuals 16 years of age and older.
This vaccine, previously known as the Pfizer-BioNTech COVID-19...
Johnson & Johnson will have a new CEO in 2022. Current chairman and CEO Alex Gorsky is transitioning to the role of executive chairman and will be replaced as CEO by Joaquin Duato, according to a...
FDA recently granted emergency use authorization for Thermo Fisher Scientific’s two PCR-based COVID-19 test kits.
The test kits, TaqPath COVID-19 Fast PCR Combo Kit 2.0 and TaqPath COVID-19...
The University of Pittsburgh Medical Center (UPMC) recently announced expanded access to its potential COVID-19 antibody treatments in outpatient and inpatient settings for eligible...
The World Health Organization (WHO) recently announced the next phase in its Solidarity trial, Solidarity PLUS, to test new COVID-19 drugs in hospitalized patients.
The trial will enroll...
FDA amends the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow for an additional dose in immunocompromised individuals.
The agency determined that the...
Novavax recently announced that a single booster dose of its COVID-19 vaccine, NVX-CoV2373, elicited a 4.6-fold increase in functional antibody titers six months after an initial two-dose...
